Medtech Firm Enovis Sets Strong 2024 Targets As Q4 Earnings Beat Expectations, Analyst Says Growth Intact

Enovis Corporation’s (NYSE:ENOV) fourth-quarter net sales reached $455 million, up 11% Y/Y, including 8% organic growth, beating the consensus of $445.36 million.

Fourth quarter results reflect continued execution in P&R, above-market growth in Recon, and the impact of recent acquisitions. 

Compared to the same quarter in 2022, net sales in Recon grew 18%, with 11% organic sales growth, and P&R grew 8%, with 6% organic sales growth.

Also Read: This Analyst Sees Durable Share Gains, Margin Expansion For Orthopedics-Focused Enovis.

Enovis reported a fourth-quarter net income from continuing operations of $3 million and an adjusted EBITDA of $82 million, or 18% of sales, …

Full story available on Benzinga.com